ECSP13012459A - Valsartan altamente cristalino - Google Patents

Valsartan altamente cristalino

Info

Publication number
ECSP13012459A
ECSP13012459A ECSP13012459A ECSP13012459A EC SP13012459 A ECSP13012459 A EC SP13012459A EC SP13012459 A ECSP13012459 A EC SP13012459A EC SP13012459 A ECSP13012459 A EC SP13012459A
Authority
EC
Ecuador
Prior art keywords
valsartan
highly crystal
highly
crystal
preparation
Prior art date
Application number
Other languages
English (en)
Inventor
Ricardo Schneeberger
Florian Andreas Rampf
Jens Burgbacher
Björn Thomas Hahn
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of ECSP13012459A publication Critical patent/ECSP13012459A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D257/04—Five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención describe una forma altamente cristalina de valsartan, composiciones farmacéuticas de la misma, y un proceso para la preparación de las mismas.
ECSP13012459 2010-08-03 2013-02-25 Valsartan altamente cristalino ECSP13012459A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US37028510P 2010-08-03 2010-08-03

Publications (1)

Publication Number Publication Date
ECSP13012459A true ECSP13012459A (es) 2013-03-28

Family

ID=44645072

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSP13012459 ECSP13012459A (es) 2010-08-03 2013-02-25 Valsartan altamente cristalino

Country Status (19)

Country Link
US (1) US20130137737A1 (es)
EP (1) EP2601180A1 (es)
JP (1) JP2013532707A (es)
KR (1) KR20130139863A (es)
CN (1) CN103052630A (es)
AR (1) AR082435A1 (es)
AU (1) AU2011287616A1 (es)
BR (1) BR112013002589A2 (es)
CA (1) CA2806657A1 (es)
CL (1) CL2013000335A1 (es)
CO (1) CO6670580A2 (es)
EC (1) ECSP13012459A (es)
MA (1) MA34580B1 (es)
MX (1) MX2013001251A (es)
PH (1) PH12013500210A1 (es)
RU (1) RU2013109365A (es)
SG (1) SG187007A1 (es)
TW (1) TW201206428A (es)
WO (1) WO2012016969A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103739564A (zh) * 2012-02-20 2014-04-23 中国科学院上海药物研究所 缬沙坦的多晶型及其制备方法
CN103435567B (zh) * 2013-09-09 2015-08-26 山东新华制药股份有限公司 缬沙坦的精制方法
CN105801506A (zh) * 2014-12-30 2016-07-27 天津法莫西医药科技有限公司 缬沙坦新晶型及其制备方法
JP2016150917A (ja) * 2015-02-17 2016-08-22 株式会社トクヤマ バルサルタンの結晶の製造方法
CN105777660A (zh) * 2016-03-29 2016-07-20 潍坊盛瑜药业有限公司 缬沙坦晶型e的诱导结晶工艺及应用

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE122010000024I1 (de) 1990-02-19 2010-07-08 Novartis Ag Acylverbindungen
CN1137887C (zh) * 2000-04-07 2004-02-11 常州四药制药有限公司 一种合成缬沙坦的改进方法
BR0112665A (pt) 2000-07-19 2003-06-24 Novartis Ag Sais
US6869970B2 (en) 2002-02-04 2005-03-22 Novartis Ag Crystalline salt forms of valsartan
WO2003089417A1 (en) 2002-04-15 2003-10-30 Dr. Reddy's Laboratories Limited Novel crystalline forms of (s)-n-(1-carboxy-2-methyl-prop-1-yl) -n-pentanoyl-n- [2’-(1h-tetrazol-5-yl-)- biphenyl-4-yl methyl] amine (valsartan)
GB0222056D0 (en) * 2002-09-23 2002-10-30 Novartis Ag Process for the manufacture of organic compounds
CN1788004A (zh) * 2003-03-17 2006-06-14 特瓦制药工业有限公司 缬沙坦的多晶型
EP1511739B1 (en) 2003-03-17 2008-04-30 Teva Pharmaceutical Industries Ltd. Polymorphs of valsartan
CZ298685B6 (cs) * 2003-05-15 2007-12-19 Zentiva, A.S. Zpusob výroby N-(1-oxopentyl)-N-[[2´-(1H-tetrazol-5-yl)[1,1´-bifenyl]-4-yl]methyl]-L-valinu (valsartanu)
ITMI20032267A1 (it) * 2003-11-21 2005-05-22 Dinamite Dipharma S P A In Forma A Bbreviata Diph Procdimento per la preparzione di valsartan e suoi intermedi
US20060270723A1 (en) 2005-01-11 2006-11-30 Tamas Koltai Process for preparing amorphous valsartan
EP1896433A4 (en) * 2005-05-25 2010-06-02 Ipca Lab Ltd NEW CRYSTALLINE FORMS OF (S) -N- (1-CARBOXY-2-METHYL-PROP-1-YL) -N-PENTANOYL-N- [2 '- (1H-TETRAZOL-5-YL) BI-PHENYL-4 ylmethyl] amine
ITMI20051989A1 (it) * 2005-10-20 2007-04-21 Dipharma Spa Procedimerntyo per la preparazione di composti antagonisti di angiotensina ii
WO2007069271A2 (en) * 2005-10-31 2007-06-21 Alembic Limited Process for the purification of (s) -n- (l-carboxy-2-methyl-prop-1-yl) -n-pentanoyl-n- [2' - (1h-tetraz0l-5-yl) bipheny l-4 -ylmethyl] -amine (valsartan)
CN1844110B (zh) * 2005-12-09 2010-07-14 浙江天宇药业有限公司 高光学纯度的缬沙坦的合成方法
CN101270096B (zh) * 2007-03-22 2011-08-03 浙江华海药业股份有限公司 一种合成缬沙坦的方法
CN100522953C (zh) * 2007-04-03 2009-08-05 浙江天宇药业有限公司 一种缬沙坦的新合成方法
ES2316281B1 (es) * 2007-05-14 2010-02-09 Quimica Sintetica, S.A. Procedimiento para la preparacion de valsartan.
CN101362728B (zh) * 2008-08-22 2011-07-20 北京赛科药业有限责任公司 一种缬沙坦的合成方法
CN101768128B (zh) * 2009-01-05 2012-10-10 浙江华海药业股份有限公司 一种含10%以上异构体的缬沙坦的精制方法
CN101475540B (zh) * 2009-01-22 2011-05-11 江苏德峰药业有限公司 一种缬沙坦的制备方法
CN101735164A (zh) * 2009-12-22 2010-06-16 北京赛科药业有限责任公司 缬沙坦中杂质f的研究及控制方法

Also Published As

Publication number Publication date
MA34580B1 (fr) 2013-10-02
PH12013500210A1 (en) 2020-10-19
CN103052630A (zh) 2013-04-17
JP2013532707A (ja) 2013-08-19
CL2013000335A1 (es) 2013-06-14
CA2806657A1 (en) 2012-02-09
TW201206428A (en) 2012-02-16
RU2013109365A (ru) 2014-09-10
AU2011287616A1 (en) 2013-02-28
MX2013001251A (es) 2013-03-18
CO6670580A2 (es) 2013-05-15
AR082435A1 (es) 2012-12-05
BR112013002589A2 (pt) 2019-09-24
KR20130139863A (ko) 2013-12-23
US20130137737A1 (en) 2013-05-30
WO2012016969A1 (en) 2012-02-09
SG187007A1 (en) 2013-02-28
EP2601180A1 (en) 2013-06-12

Similar Documents

Publication Publication Date Title
BR112013019223A2 (pt) forma de dosagem para liberação modificada, processo para a fabricação de um comprimido e processo para a fabricação de uma forma de dosagem oral
DK2709667T3 (da) Bio-orthogonal lægemiddelaktivering
WO2012068441A3 (en) Intedanib salts and solid state forms thereof
ZA201206254B (en) Novel salts for the manufacture of pharmaceutical compositions
BR112013018875A2 (pt) métodos e composições para a preparação de noribogaína a partir de voacangina
BR112013002591A2 (pt) polialfaolefinas de elevada viscosidade estáveis em cisalhamento
WO2012070062A3 (en) Novel polymorph of nilotinib hydrochloride
EP2665471A2 (en) Controlled release oral pharmaceutical dosage forms comprising mgbg
ES2421956A1 (es) Nueva forma cristalina de sulfato de sitagliptina
WO2012107890A3 (en) Crystal forms of lurasidone chlorhydrate
HRP20260138T1 (hr) Postupak priprave 2,3,3,3-tetrafluoropropena
BR112014009297A2 (pt) processos para a preparação de 6-cloro-2,3,4,9-tetrahidro-1 h-carbazol-1-carboxamida e dos seus precursores
WO2012174229A3 (en) Methods for the synthesis and purification of deoxycholic acid
PH12013500210A1 (en) Highly crystalline valsartan
BR112015002979A2 (pt) forma cristalina, e, composição farmacêutica
HUE045737T2 (hu) Eljárás gyógyszerészeti tisztaságú kristályok elõállítására
BR112013015903A2 (pt) polimorfo cristalino, processo para preparar um polimorfo, composição farmacêutica, forma purificada do polimorfo, uso de um polimorfo, processo para preparar um composto, e, composto.
AU2011100382A4 (en) Now Reminder
EP2665701A2 (en) Diazeniumdiolate derivatives
TN2013000035A1 (en) Highly crystalline valsartan
AU2011901460A0 (en) Starfish
AU2011905393A0 (en) Pharmaceutical Composition
AU2011900519A0 (en) Drug compositions for the treatment of insomnia
AU2011904699A0 (en) Pharmaceutical compositions
HK1195094A (en) Calcium sequestering composition